Jacob de Bakker, Hedde Biesma, Tanya Soeratram, Jacqueline Egthuijsen, Tim de Back, Marc Besselink, Louis Vermeulen, Bauke Ylstra, Nicole van Grieken, Geert Kazemier
{"title":"Molecular Classification of Resected Primary Duodenal Adenocarcinoma","authors":"Jacob de Bakker, Hedde Biesma, Tanya Soeratram, Jacqueline Egthuijsen, Tim de Back, Marc Besselink, Louis Vermeulen, Bauke Ylstra, Nicole van Grieken, Geert Kazemier","doi":"10.1002/gcc.70061","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The molecular and histological characteristics of primary duodenal adenocarcinoma (DA) have been poorly described, which hampers the development of new treatment options. This study aimed to characterize the landscape of chromosomal copy number aberrations (CNAs), microsatellite instability status, and tumor–stroma content, and their association with clinicopathological characteristics of patients with DA.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>DNA was extracted from tumor tissues of patients who underwent a primary surgical resection for DA in a single center (2000–2019). Shallow whole genome sequencing (sWGS) was performed to identify chromosomal CNAs and the genomic instability index (GII), for which 25% of the genome was altered, was used to classify tumors as CNA<sup>low</sup> or CNA<sup>high</sup>. A PCR-based assay was performed to classify tumors as microsatellite stable (MSS) or instable (MSI). Immunohistochemistry and digital image analysis were performed to determine the tumor–stroma content, for which 50% stroma content was used to classify tumors as stroma<sup>low</sup> or stroma<sup>high</sup>.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 74 patients with resected DA, sWGS identified 39 (52.7%) CNA<sup>low</sup> and 35 (47.3%) CNA<sup>high</sup> tumors. Overall, 16 (21.6%) DAs were MSI. All MSI tumors were CNA<sup>low</sup>. The tumor–stroma content was low in 51 (68.9%) and high in 23 (31.1%) of DAs. CNA status was most predictive for 5-year overall survival: 45.5% for patients with CNA<sup>low</sup> compared to 31.0% for patients with CNA<sup>high</sup> DA (HR 2.20, 95% CI 1.12–4.30, <i>p</i> = 0.02).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>About half of resected DAs had CNA<sup>low</sup>, which was associated with the most favorable prognosis. Subgrouping of DA could be used for patient stratification in future trials testing novel therapies.</p>\n </section>\n </div>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 7","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70061","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.70061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
The molecular and histological characteristics of primary duodenal adenocarcinoma (DA) have been poorly described, which hampers the development of new treatment options. This study aimed to characterize the landscape of chromosomal copy number aberrations (CNAs), microsatellite instability status, and tumor–stroma content, and their association with clinicopathological characteristics of patients with DA.
Methods
DNA was extracted from tumor tissues of patients who underwent a primary surgical resection for DA in a single center (2000–2019). Shallow whole genome sequencing (sWGS) was performed to identify chromosomal CNAs and the genomic instability index (GII), for which 25% of the genome was altered, was used to classify tumors as CNAlow or CNAhigh. A PCR-based assay was performed to classify tumors as microsatellite stable (MSS) or instable (MSI). Immunohistochemistry and digital image analysis were performed to determine the tumor–stroma content, for which 50% stroma content was used to classify tumors as stromalow or stromahigh.
Results
Among 74 patients with resected DA, sWGS identified 39 (52.7%) CNAlow and 35 (47.3%) CNAhigh tumors. Overall, 16 (21.6%) DAs were MSI. All MSI tumors were CNAlow. The tumor–stroma content was low in 51 (68.9%) and high in 23 (31.1%) of DAs. CNA status was most predictive for 5-year overall survival: 45.5% for patients with CNAlow compared to 31.0% for patients with CNAhigh DA (HR 2.20, 95% CI 1.12–4.30, p = 0.02).
Conclusion
About half of resected DAs had CNAlow, which was associated with the most favorable prognosis. Subgrouping of DA could be used for patient stratification in future trials testing novel therapies.
对原发性十二指肠腺癌(DA)的分子和组织学特征描述甚少,这阻碍了新的治疗选择的发展。本研究旨在描述染色体拷贝数畸变(CNAs)、微卫星不稳定状态和肿瘤基质含量的特征,以及它们与DA患者临床病理特征的关系。方法从单中心(2000-2019年)接受原发性DA手术切除的患者肿瘤组织中提取DNA。浅全基因组测序(sWGS)用于鉴定染色体CNAs,基因组不稳定性指数(GII)用于将肿瘤分类为CNAlow或CNAhigh,其中25%的基因组发生了改变。采用pcr法将肿瘤分为微卫星稳定型(MSS)和不稳定型(MSI)。通过免疫组化和数字图像分析确定肿瘤间质含量,其中间质含量为50%的肿瘤分为stromalow或stromahigh。结果74例DA切除患者中,sWGS检出39例(52.7%)CNAlow肿瘤,35例(47.3%)CNAhigh肿瘤。总的来说,16个da(21.6%)是MSI。所有MSI肿瘤均为cnlow。肿瘤间质含量低51例(68.9%),高23例(31.1%)。CNA状态最能预测5年总生存率:cnlow患者为45.5%,而cna高DA患者为31.0% (HR 2.20, 95% CI 1.12-4.30, p = 0.02)。结论约一半的切除DAs存在CNAlow,其预后较好。DA的亚组可用于未来试验新疗法的患者分层。
期刊介绍:
Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.